Hennion & Walsh Asset Management’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.74M Buy
171,470
+57,959
+51% +$2.57M 0.28% 74
2026
Q1
$3.37M Buy
113,511
+14,282
+14% +$427K 0.11% 234
2025
Q4
$3.79M Buy
99,229
+62,419
+170% +$2.03M 0.13% 199
2025
Q3
$880K Buy
36,810
+15,151
+70% +$285K 0.03% 542
2025
Q2
$321K Buy
+21,659
New +$359K 0.01% 792
2024
Q4
Sell
-36,604
Closed -$512K 911
2024
Q3
$512K Sell
36,604
-3,844
-10% -$40K 0.02% 610
2024
Q2
$332K Sell
40,448
-342
-0.8% -$2.3K 0.02% 704
2024
Q1
$314K Buy
40,790
+5,123
+14% +$43.2K 0.02% 678
2023
Q4
$321K Sell
35,667
-40,206
-53% -$293K 0.02% 664
2023
Q3
$678K Sell
75,873
-5,230
-6% -$73.8K 0.04% 446
2023
Q2
$1.25M Buy
81,103
+1,163
+1% +$21.2K 0.07% 335
2023
Q1
$1.8M Buy
79,940
+4,474
+6% +$95.1K 0.11% 227
2022
Q4
$1.59M Buy
75,466
+31,152
+70% +$660K 0.1% 243
2022
Q3
$1.09M Sell
44,314
-1,486
-3% -$38.4K 0.07% 299
2022
Q2
$1.11M Buy
45,800
+4,422
+11% +$111K 0.07% 294
2022
Q1
$1.07M Buy
41,378
+16,339
+65% +$434K 0.06% 330
2021
Q4
$777K Buy
+25,039
New +$705K 0.04% 434

Other funds holding TVTX

Hennion & Walsh Asset Management's TVTX Position: Q2 2026 in Review

Hennion & Walsh Asset Management increased its Travere Therapeutics (TVTX) stake by 51% in Q2 2026, buying an estimated $2.57M and bringing the position to 171,470 shares worth $9.74M. The position accounts for 0.28% of the portfolio, ranked #74.

Hennion & Walsh Asset Management first reported a position in TVTX in Q4 2021 and has held it in 17 quarters since. 35 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Hennion & Walsh Asset Management held 171,470 shares of Travere Therapeutics worth $9.74M as of Q2 2026.
  • Hennion & Walsh Asset Management bought 57,959 Travere Therapeutics shares in Q2 2026, an estimated $2.57M.
  • Travere Therapeutics made up 0.28% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #74 holding.
  • Hennion & Walsh Asset Management first reported a position in Travere Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • 35 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.